RxDoctor Payments Data

Tara Garza

Nurse Practitioner · Bryan, OHNPI 1598165888

Payments from drug & device makers

$553in general payments, 2019–2025

Across 17 payments — averaging $32.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$170
  • Pharmacosmos Therapeutics Inc.$125
  • Indivior Inc.$120
  • Inspire Medical Systems, Inc.$39
  • Axsome Therapeutics, Inc.$39
  • AstraZeneca$24
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$553100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$553 in reported general payments places this provider in the 75th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$29,448
Medicare patients
98
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban47$44,255
OzempicSemaglutide25$36,810
JardianceEmpagliflozin30$34,275
TrulicityDulaglutide21$30,439
JanuviaSitagliptin Phosphate20$24,646
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$16,166
MyrbetriqMirabegron11$11,131
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,172
SymbicortBudesonide/Formoterol Fumarate12$4,226
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl19$2,706
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,490
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$1,974
Levothyroxine Sodium166$1,652
Metoprolol Succinate135$1,652
Atorvastatin Calcium216$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$36,81025 claims
AstraZenecaSymbicort$24$4,22612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Bryan

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →